Redose
Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH) with an important distinction from most peptides in research use: it is FDA-approved. Since November 2010, it has been marketed under the brand name Egrifta (and its successor formulations Egrifta SV and Egrifta WR) for a specific, well-characterized clinical indication. Understanding where the evidence is strong and where it remains preliminary is essential for anyone researching this compound.
What is Tesamorelin
Tesamorelin is a stabilized, full-sequence synthetic analog of human GHRH, modified at its N-terminus with the addition of a trans-2-hexadecenoic acid group. This chemical modification confers resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), which normally breaks down endogenous GHRH within minutes of secretion. The result is a peptide that retains full receptor specificity while remaining active long enough to produce meaningful downstream effects after subcutaneous injection.
It was developed by Theratechnologies and is the only GHRH analog to achieve regulatory approval for an adult metabolic indication anywhere in the world. Its approved use is the reduction of excess abdominal fat in HIV-infected adults who have developed lipodystrophy, a metabolic complication of long-term antiretroviral therapy.
How it Works
Tesamorelin binds selectively to GHRH receptors on somatotroph cells in the anterior pituitary. This binding triggers the synthesis and release of endogenous growth hormone (GH) in a pulsatile pattern, preserving the natural feedback relationship between GH, IGF-1, and the hypothalamus. This is mechanistically distinct from administering exogenous recombinant human GH directly.
The downstream effects of elevated GH and IGF-1 include enhanced lipolysis, particularly in metabolically active visceral fat depots. Visceral adipose tissue (VAT) is more sensitive to GH-driven lipolysis than subcutaneous fat, which explains the compound's selective effect on abdominal fat rather than total body fat. Secondary metabolic effects observed in trials include improvements in triglyceride levels and cholesterol ratios, consistent with GH's known roles in lipid metabolism.
Plasma half-life of Tesamorelin is approximately 8 minutes after subcutaneous administration, though its biological effects persist considerably longer because GH secretion continues after the peptide itself is cleared.
What the Research Says
The evidence base for Tesamorelin is unusually robust for a peptide compound, anchored by two multicenter, randomized, double-blind, placebo-controlled Phase 3 trials involving more than 800 participants.
Visceral fat reduction: Across both Phase 3 trials, patients receiving Tesamorelin 2 mg daily showed approximately 15 to 16 percent reductions in VAT at 26 weeks, compared with increases of approximately 5 percent in placebo groups. Extension-phase data at 52 weeks showed responders maintaining roughly 18 percent reductions. These results were statistically significant and clinically meaningful by FDA pre-specified thresholds.
Lipid profiles: The same trials observed reductions in triglycerides (approximately 50 mg/dL versus a slight increase in placebo) and improvements in total cholesterol to HDL-cholesterol ratios, suggesting a favorable cardiovascular metabolic effect in the studied population.
Body composition: Tesamorelin had a weight-neutral overall effect and was associated with modest increases in lean body mass (reported as up to approximately 5 lbs in labeling data), without significant changes in subcutaneous fat.
Investigational areas: Smaller and earlier-phase studies have explored Tesamorelin in non-HIV populations, including research into cognitive outcomes in older adults and effects on hepatic fat in NAFLD. These areas remain investigational; the evidence is preliminary and should not be interpreted as established efficacy outside the approved HIV lipodystrophy indication.
One important caveat across all indications: discontinuation of Tesamorelin results in reversal of the visceral fat reduction over several months. The effect is not permanent and requires continued use to maintain.
Typical Dosing
In the FDA-approved protocol, Tesamorelin is administered as a 2 mg dose once daily by subcutaneous injection into the abdomen, rotating sites within that region. The approved formulation (Egrifta WR) is reconstituted weekly and administered daily, requiring less injection volume than prior formulations.
In clinical research and off-label protocols outside the approved indication, reported dosing ranges commonly cited are 1 to 2 mg per day, typically once daily in the morning. Some investigational protocols have used 1 mg daily in older adults or those concerned about IGF-1 elevation. Dosing outside the approved indication is not standardized and varies meaningfully across sources.
Regardless of the dose used, Tesamorelin must be reconstituted properly before injection. See how to reconstitute peptides for a step-by-step guide, and review injection site rotation to reduce injection site reactions over a longer protocol.
Dosing information here reflects ranges commonly reported in clinical research and approved labeling. It is not personal medical instruction.
Side Effects and Safety
Tesamorelin's safety profile is better characterized than most peptides because of its Phase 3 clinical trial history. Key considerations include:
| Category | Detail |
|---|---|
| Injection site reactions | Erythema, pruritus, pain (most common; reported in the FDA label as greater than 5%) |
| Fluid retention | Peripheral edema, particularly at higher GH exposure |
| Joint and muscle | Arthralgia, myalgia |
| IGF-1 elevation | IGF-1 rises predictably; monitoring is recommended to avoid supraphysiological levels |
| Glucose metabolism | Tesamorelin may impair glucose tolerance; use with caution in pre-diabetic or diabetic individuals |
| Hypersensitivity | Allergic reactions reported in approximately 3 to 4 percent of trial participants |
Contraindications (from FDA labeling): active malignancy, disruption of the hypothalamic-pituitary axis (such as pituitary tumors, prior cranial irradiation, or hypopituitarism), known hypersensitivity to Tesamorelin or its excipients, and pregnancy. Long-term cardiovascular safety has not been established.
IGF-1 monitoring during use is clinically standard. Elevated IGF-1 is associated with increased neoplasm risk over the long term, and the FDA label specifically flags this. Regular laboratory monitoring is not optional when using this compound.
Tracking Tesamorelin with Redose
Tesamorelin protocols involve daily subcutaneous injections with careful attention to timing, dose, and site rotation to minimize tissue reactions. Redose makes that straightforward: log each dose in one tap, track your injection sites on a body map so no single area gets overloaded, and use the built-in inventory tracker to know exactly when your supply needs replenishing before you run out mid-protocol.
The reconstitution calculator at /calculators handles the math for mixing vial sizes with bacteriostatic water, converting between mg and injection volumes so there is no guesswork at the time of administration. Download Redose at /#download for iPhone and Android.
This profile is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.